NexImmune and the Multiple Myeloma Research Foundation (MMRF) discuss collaborative opportunities to advance promising new therapies
NexImmune and the Multiple Myeloma Research Foundation (MMRF) have entered into a partnership to advance a promising new therapy into clinical trials for multiple myeloma patients. The NexImmune team was invited to the offices of MMRF to discuss a broad range of collaborative opportunities that focus on advancing the health of patients diagnosed with Multiple Myeloma. The MMRF’s newly formed Myeloma Investment Fund (MIF) mission is to support promising companies and technologies by accelerating the clinical development of innovative therapies with potential to benefit myeloma patients. The MIF has made an equity investment in NexImmune to help support the initial clinical development of NEXI-002 for patients with relapsed / refractory Multiple Myeloma, and to further help develop the Company’s Artificial Immune Modulatory (AIM) technology platform.
Paul Giusti, President & CEO MMRF, Scott Carmer, CEO NexImmune, Dana LaForge, Chairman of the Board MMRF
Kristi Jones, COO NexImmune, Paul Giusti, President and CEO MMRF, Joshua Barer, Managing Director, Barer & Sons, back row, Peter Kosa, Managing Director Myeloma Investment Fund, Mathias Oelke, SVP, NexImmune, Scott Carmer, CEO NexImmune.